Moleculin Biotech Inc Cash Flow-to-Debt Ratio
Moleculin Biotech Inc cash flow-to-debt ratio. Moleculin Biotech Inc (MBRX) has a Cash Flow-to-Debt Ratio of -0.75x as of December 2025, meaning its operating cash flow of $-5.37 Million could theoretically repay -1% of its total liabilities ($7.12 Million) in one year. Check Moleculin Biotech Inc (MBRX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Moleculin Biotech Inc (2015–2025)
Cash flow-to-debt ratio of Moleculin Biotech Inc from 2015 to 2025. Historical debt coverage capacity for Moleculin Biotech Inc across 11 annual periods. Also explore net asset growth rate of Moleculin Biotech Inc to track the company's year-over-year net asset growth rate.
Moleculin Biotech Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Moleculin Biotech Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Moleculin Biotech Inc. For the full cash flow conversion analysis, see MBRX cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.19x | $-22.73 Million | $7.12 Million | ▼ -46.5% |
| 2024 | -2.18x | $-23.86 Million | $10.95 Million | ▼ -9.8% |
| 2023 | -1.98x | $-24.10 Million | $12.14 Million | ▲ +62.4% |
| 2022 | -5.28x | $-27.64 Million | $5.23 Million | ▼ -42.1% |
| 2021 | -3.72x | $-18.95 Million | $5.10 Million | ▼ -135.8% |
| 2020 | -1.58x | $-17.77 Million | $11.27 Million | ▲ +11.4% |
| 2019 | -1.78x | $-17.20 Million | $9.66 Million | ▲ +22.5% |
| 2018 | -2.30x | $-12.20 Million | $5.31 Million | ▲ +25.8% |
| 2017 | -3.10x | $-7.32 Million | $2.37 Million | ▼ -17.8% |
| 2016 | -2.63x | $-3.76 Million | $1.43 Million | ▼ -379.6% |
| 2015 | -0.55x | $-423.51K | $772.79K | — |